Literature DB >> 7923827

Insulin sensitivity and insulin clearance in cystic fibrosis patients with normal and diabetic glucose tolerance.

S Lanng1, B Thorsteinsson, M E Røder, J Nerup, C Koch.   

Abstract

OBJECTIVE: We studied glucose metabolism and insulin kinetics in cystic fibrosis patients with diabetic and normal glucose tolerance.
DESIGN: Measurements of blood glucose and serum free insulin concentrations during hyperinsulinaemic normoglycaemic clamp and post-clamp insulin decay, followed by the calculation of insulin sensitivity (M-value and M/I ratio), insulin clearance rate, serum half-life and apparent distribution space for insulin.
SUBJECTS: Cystic fibrosis patients, age range 20-29 years, with diabetes mellitus (n = 10) and normal glucose tolerance (n = 10), and 10 age-matched control subjects.
RESULTS: During the glucose clamp, diabetic cystic fibrosis patients needed less glucose than cystic fibrosis patients with normal glucose tolerance and control subjects (M-value), and steady-state serum insulin concentrations were lower in cystic fibrosis patients with diabetic and normal glucose tolerance than in control subjects. The quantity of glucose metabolized per unit of serum insulin concentration (M/I ratio) was similar in the three study groups (median approximately 145 (mumol/kg/min)/(nmol/l); range 70-252). Insulin clearance rates were higher in cystic fibrosis patients with diabetic (24.4 (19.3-29.9) ml/kg/min) and normal (22.6 (14.9-28.4) ml/kg/min) glucose tolerance than in control subjects (17.5 (15.9-24.2) ml/kg/min). Although insulin clearance rates were inversely related to body mass index (R(S) = -0.59, P < 0.001), the higher insulin clearance rates in CF patients cannot be accounted for solely by differences in body mass index since the insulin clearance rates were similarly increased in patients with body mass index above and below 20 kg/m2 (22.7 (14.9-28.4) and 24.4 (19.3-29.9) ml/kg/min, respectively). Serum half-lives for insulin were shorter in cystic fibrosis patients (approximately 4.3 (3.2-7.2) min) than in control subjects (5.9 (3.8-12.5) min), whereas the apparent distribution spaces for insulin were similar in the three study groups (approximately 150 (88-391) ml/kg).
CONCLUSIONS: Insulin sensitivity, calculated as the quantity of glucose metabolized per kg body weight per unit of serum insulin concentration, is normal in cystic fibrosis patients with normal glucose tolerance and with well controlled diabetes mellitus. The insulin clearance rate is increased in cystic fibrosis patients with diabetic and normal glucose tolerance, owing to a shorter serum half-life of insulin, whereas the apparent distribution space for insulin is normal.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923827     DOI: 10.1111/j.1365-2265.1994.tb02533.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  14 in total

Review 1.  Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?

Authors:  Lee Dobson; Christopher D Sheldon; Andrew T Hattersley
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

2.  Islet Hormone and Incretin Secretion in Cystic Fibrosis after Four Months of Ivacaftor Therapy.

Authors:  Andrea Kelly; Diva D De Leon; Saba Sheikh; Devaney Camburn; Christina Kubrak; Amy J Peleckis; Darko Stefanovski; Denis Hadjiliadis; Michael R Rickels; Ronald C Rubenstein
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

3.  Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure.

Authors:  Rebecca L Hull; Ronald L Gibson; Sharon McNamara; Gail H Deutsch; Corinne L Fligner; Charles W Frevert; Bonnie W Ramsey; Srinath Sanda
Journal:  Diabetes Care       Date:  2018-02-01       Impact factor: 19.112

4.  Reduced insulin sensitivity is correlated with impaired sleep in adolescents with cystic fibrosis.

Authors:  Stacey L Simon; Tim Vigers; Kristen Campbell; Laura Pyle; Rachael Branscomb; Kristen J Nadeau; Christine L Chan
Journal:  Pediatr Diabetes       Date:  2018-08-01       Impact factor: 4.866

5.  Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets.

Authors:  Alicia K Olivier; Yaling Yi; Xingshen Sun; Hongshu Sui; Bo Liang; Shanming Hu; Weiliang Xie; John T Fisher; Nicholas W Keiser; Diana Lei; Weihong Zhou; Ziying Yan; Guiying Li; Turan I A Evans; David K Meyerholz; Kai Wang; Zoe A Stewart; Andrew W Norris; John F Engelhardt
Journal:  J Clin Invest       Date:  2012-09-17       Impact factor: 14.808

Review 6.  Diagnosis, screening, and management of cystic fibrosis-related diabetes.

Authors:  Antoinette Moran
Journal:  Curr Diab Rep       Date:  2002-04       Impact factor: 4.810

7.  Reduced pancreatic insulin release and reduced peripheral insulin sensitivity contribute to hyperglycaemia in cystic fibrosis.

Authors:  R W Holl; E Heinze; A Wolf; M Rank; W M Teller
Journal:  Eur J Pediatr       Date:  1995-05       Impact factor: 3.183

8.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

Review 9.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 10.  Diabetes in cystic fibrosis.

Authors:  B Yung; M E Hodson
Journal:  J R Soc Med       Date:  1999       Impact factor: 18.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.